Drug Trial Radar · NCT06385925
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
570
Planned (sponsor's estimate)
Start
Apr 29, 2024
Primary completion
Oct 30, 2027
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Tyligand Pharmaceuticals (Suzhou) LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1a dose escalation/confirmation part, phase 1b dose randomization part and phase 2 dose expansion parts of TSN1611 as monotherapy or in combination with other anti-cancer therapies. This study will evaluate the efficacy of TSN1611 at RP2D(s) through ORR using RECIST version 1.1, and determine and confirm the MTD/RP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with cetuximab and FOLFIRI, in combination with gemcitabine and albumin-bound paclitaxel in subjects with selected solid tumors.
Conditions
- Malignant Neoplasm
Interventions
TSN1611Drug
TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
TSN1611Drug
TSN1611 at the assigned dose level, orally, BID, combined with cetuximab, IV, every 2 weeks (Q2W), continuously in 28-day cycles
TSN1611Drug
TSN1611 at the assigned dose level, orally, BID, combined with GnP regimen (gemcitabine and nab-paclitaxel), IV, on Day 1, 8 and 15, continuously in 28-day cycles
TSN1611Drug
TSN1611 BID everyday and Patients will be administered with mFOLFOX6 on Days 1 and 2, every 2 weeks.
TSN1611Drug
TSN1611 at the assigned dose level, orally, BID, combined with cetuximab and FOLFIRI (irinotecan, leucovorin, and fluorouracil), IV, every 2 weeks (Q2W), continuously in 28-day cycles,
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities (DLTs) in phase 1 partTime frame: 21 days
- Objective response rate (ORR) in phase 2 partTime frame: Up to 3 years
- Dose limiting toxicities (DLTs) in phase 1b part of TSN1611 Combination TherapyTime frame: 28 days
- Objective response rate (ORR) in phase 2 part of TSN1611 Combination TherapyTime frame: Up to 3 years
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Beijing Cancer Hospital, Beijing, China
Beijing, China · Recruiting
Peking Union Medical College Hospital
Beijing, China · Not yet recruiting
Shanghai Chest Hospital, Shanghai, China
Shanghai, China · Recruiting
Shanghai Zhongshan Hospital, Shanghai, China
Shanghai, China · Recruiting
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Peking University First Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
The First Affiliated Hospital of Nanchang University - Donghu District
Nanchang, Jiang, China · Recruiting
Linyi Cancer Hospital
Linyi, Shandong, China · Recruiting
Ruijin Hospital-Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Sir Run Run Shaw Hospital - Zhejiang University School of Med
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital - Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.